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Abstract
Objectives: Oral cancer is a worldwide phenomenon. It is thought to develop in a number of premalignant lesions. 
Protooncogene c fos is a known transformer of premalignant to malignant lesions. However, its role in oral carcino-
genesis is not yet known.
Study design: A total of 130 cases were studied comprising of premalignant lesions (n=50), squamous cell carcinoma 
(n=50) and controls (n=30). c fos expression was studied by immunohistochemistry.
 Results: Premalignant lesions of oral cavity occurred at a lower age group (mean 39.2 years) compared to squamous 
cell carcinoma (mean 51.8 years), p <0.001. Mean c fos percentage positivity in squamous cell carcinomas (SCC), 
premalignant lesions and controls was 44.5±36.9%, 11.4±18.8% and 1.23±2.6% respectively, the differences were 
highly significant (p<0.001). c fos positivity also increased from mild (10.85±14.23%) to moderate dysplasia (19.64 
±26.05%).
Conclusions: The serially increasing c fos expression from normal mucosa to premalignant lesions to SCC and in 
dysplasias suggests that it could be an early gene to get activated and form transcription factor activator protein 
–1(AP-1).
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Introduction
Oral cancer is one of the ten most common cancers in the 
world (1). Its high frequency in Central and South East 
Asian countries has been well documented. Epidemiolo-
gical studies have shown that the worldwide incidence and 
mortality rates for oral cancer have increased considerably 
over the last decade. There were annual increases in oral 
cancer mortality from 1975-94, of 25% and 9% in males 
and females, respectively (2).
 Oral cancer is preceded by a number of precursor lesions; 
these include leucoplakia, erythroplakia, lichen planus and 
oral submucous fibrosis. Various factors such as tobacco, 
alcohol and diet (1) have been implicated in the causation 
of these premalignant and malignant lesions.
Oral cancer is amenable to primary prevention. In India 
and its subcontinent, tobacco is the single most important 
causative agent. It is used in various forms, most popular 
being chewing, either alone or in combination with areca 
nut and betel leaves.
The proto-oncogene c-fos is a major nuclear target for 
signal transduction pathways involved in the regulation of 
cell growth, differentiation and transformation (3). c fos 
protooncogene has a cellular homologue of v fos which is 
the transforming gene identified originally in the FBJ mu-
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rine osteosarcoma virus(3). Under normal circumstances c 
fos plays an important role in cell differentiation in various 
organs. The flip side to differentiation is tumorigenesis, 
as happens when c fos gets over expressed, leading to 
development of osteosarcomas and chondrosarcomas(3). 
Thus, this paper aims to find whether similar carcinogenic 
process is involved in oral carcinogenesis.
Materials and Methods
A total of  130 cases were biopsied. These cases were 
further divided into premalignant (n=50) and malignant 
lesions (n=50) of  oral cavity. 30 cases of  normal oral 
mucosa with no evidence of dysplasia served as controls. 
The premalignant lesions were clinically diagnosed as leu-
coplakia and oral submucous fibrosis. These lesions were 
graded into mild and moderate dysplasia (4). None of the 
premalignant cases had histological evidence of severe dys-
plasia. A detailed history in a printed questionnaire form 
with special emphasis on tobacco, betel quid and betel nut 
chewing and cigarette and bidi smoking was recorded. All 
the biopsies were processed routinely for histopathological 
diagnosis and multiple sections were cut from paraffin em-
bedded blocks for c-fos immunohistochemical staining.
- Immunohistochemistry of c fos
Immunohistochemistry for c fos was done on 4-micron 
thick paraffin sections using the standard peroxidase an-
tiperoxidase method. Positive and negative controls were 
put up with every batch. 4-micron paraffin sections were 
brought to water. Blocking was done by 0.03% hydrogen 
peroxide for 30 minutes. Non-specific blocking was done 
by 5 % skimmed milk for 30 minutes. After washing with 
PBS, primary antibody (Novocastra, lyophilized mouse 
anti-human, dilution 1in 20) was put and kept overnight 
at 4 degrees in a moist chamber. Secondary antibody 
(Novocastra) was added at room temperature for 30 
minutes followed by tertiary antibody (Novocastra) and 
chromogen DAB. The sections were counterstained with 
hematoxylin. Only nuclear staining was considered positi-
ve. A total of 500 cells were counted at 450 magnifications 
and percentage of positive cells was calculated in each 
case. This was expressed as percentage positivity of c fos. 
Adding the c fos percentage positivity of individual cases 
and dividing by the total number of cases also calculated 
the mean percentage c fos positivity of the group (control, 
premalignant and malignant). 
- Statistical analysis
Kruskal – Wallis one-way analysis of variance was done 
for comparison of percentage positivity between various 
groups. The p value of <0.05 was taken as significant while 
p < 0.01 was highly significant.
Results
- Age and sex distribution:
All the cases were Indians. In the squamous cell carcinoma 
(SCC) group there were 45 males and 5 females. The ages 
ranged from 30-80 years with a mean age of 51.8 years. 
Largest number of cases was in the age group more than 
sixty years (Table 1). The premalignant group comprised 
of 40 males and 10 females. The ages ranged from 18-65 
years, the mean age being 39.2 years. The maximum num-
ber of cases was in the age group 20-29 years (Table 1). 
This difference in age distribution between SCC and pre-
malignant lesions was statistically significant (p<0.001). 
In the control group there were 25 males and 5 females. 
The mean age was 36.6 years (range 22-62 years). Largest 
number of cases was in the age group 30-39 years (Table 
1). There was no relation of c fos with age and gender.
- c-fos Expression 
* Squamous cell carcinoma group
Thirty five out of  fifty (70 %) cases of  squamous cell 
carcinoma showed c fos positivity; the mean percentage 
positivity of the group being 44.5±36.9 % ( Table 2, Fi-
gure1).   
   





M      F M      F M    F
10-19 0         0 1      1 0      0
20-29 0         0 13      3 7      0
30-39 4         2 5       1 9      1
40-49 13         2 8       2 6      2
50-59 11         1 8       2 2      1
> 60 17         0 5        1 1      1
Total 45        5 40      10 25   5
Table 1. Age and sex distribution in squamous cell carcinoma, 
premalignant lesions and controls.
SCC: Squamous cell carcinoma, M: Males, F: Females
Med Oral Patol Oral Cir Bucal. 2008 Nov 1;13(11):E683-6.                                                                                                                                                                                  c fos expression in oral cancers                                                                             Med Oral Patol Oral Cir Bucal.  2008 Nov 1;13(11):E683-6.                                                                                                                                                                                 c fos expression in oral cancers 
E685
* Premalignant group
Nineteen out of fifty (38%) premalignant cases showed 
c-fos positivity; mean positivity was 11.4±18.8 % (Table 
2). The premalignant cases showed thirty-six cases of mild 
dysplasia, twelve of which (33%) showed c fos positivity; 
mean positivity being 10.85% ±14.23%. Out of remaining 
fourteen cases with moderate dysplasia, seven (50%) were 
c fos positive, mean positivity being 19.64 ±26.05%.  There 
was no case of severe dysplasia.
* Controls
Five out of thirty (16%) cases of controls (normal mu-
cosa) were positive for c fos. However the intensity and 
percentage positivity was low as compared with dysplastic 
and malignant cases. The mean c fos percentage positivity 
was 1.23 ± 2.6%.
- Statistical comparison between different lesions
The mean percentage c fos positivity in squamous cell 
carcinoma group (44.5 ± 36.9%) was significantly higher 
than the controls (1.23 ± 2.6%) p<0.001 (Table 2). c fos 
expression of squamous cell carcinoma group was also 
significantly higher than that of  premalignant group 
(p<0.001). 
The premalignant group also had a significantly higher 
c-fos percentage positivity (11.4 ±18.8%) than that of 
controls (1.23 ± 2.6%), p<0.001 (Table 2). c fos percentage 
positivity in mild dysplasia was 10.85% ± 14.23% which 
was also significantly higher than that of control group 
p<0.001, (Table 2).  c fos expression increased from mild 
to moderate dysplasia (19.64 ± 26.05%). However the 
differences were not statistically significant. 
Thus c fos expression increased serially from normal 
mucosa (1.23 ± 2.6%) to premalignant lesions (11.4 ± 
18.8%) to squamous cell carcinoma (44.5 ± 36.9%). This 
increasing expression of c fos was statistically significant 
(p<0.001).
Discussion
Various risk factors have been implicated in the causation 
of oral cancer. These include use of tobacco in a variety 
of forms like smoking, chewing, etc (5, 6).  Alcohol use 
has also been implicated in the etiology of oral cancer and 
has a synergistic effect on tobacco users (7). Other factors 
include diet, oral hygiene, etc. A continuous exposure to 
these carcinogenic substances leads to development of 
various premalignant lesions. However, there is a time lag 
between the appearance of premalignant lesions and its 
progression to carcinoma as was seen in our study. The 
majority of premalignant lesions were in the age group 
of  20-29 years compared to squamous cell carcinoma 
where majority occurred in more than sixty years age 
group. The mean age of premalignant lesions was 39.2 
years while SCC showed a mean age of 51.8 years. Thus 
squamous cell carcinoma developed almost after a decade 
of premalignant lesions. This is possibly the time taken 
by these premalignant lesions to progress to malignant 
transformation.
Unlike other countries oral and oropharyngeal carcinoma 
is the commonest carcinoma in Indian males, the male: 
female ratio being 2.3:1. We also found a male prepon-
derance. This predilection for males is due to high use 
of tobacco in its various forms, chewing being the most 
popular. Tobacco is chewed alone or in combination with 
areca nut and betel leaves. This exposes the oropharyngeal 
mucosa to multiple carcinogenic substances not only from 
tobacco but also from areca nut (8, 9).
Carcinogens in tobacco smoke are known to cause squa-
mous cell carcinoma of various organs and it probably 
requires repeated exposure (5). Tobacco derived carcino-
gens probably act in a multistep carcinogenesis to induce 
c fos proto oncogene (10). This is a major nuclear target 
for signal transduction pathways involved in the regulation 
of cell growth, differentiation and transformation (3). The 
proto-oncogene c fos encodes a nuclear DNA binding 
phosphoprotein that together with the product of  the 
proto-oncogene c Jun or other members of Jun family 
forms the heterodimeric transcription factor AP-1(11) that 
plays a pivotal role during tumorigenic transformation. 
Over expression of c fos has been found in a number of 
malignancies such as cervical cancer (12), lung cancers 
(13), pancreatic carcinomas (14), osteosarcomas (15), 
hepatocellular carcinoma (16) and colorectal adenoma 
(17). There are scarce reports on the role of c fos in oral 
carcinogenesis. Turatti et al (18) reported intense c fos 
expression in normal mucosa, reduced in mild dysplasia 
and increased in moderate dysplasia and squamous cell 
cancer. Our study differs from that of Turatti et al. Ours 
is a larger study of 130 cases reflecting a more relevant 
statistical correlation. Furthermore, we report a serially in-
Group
Number of cases
(Number of positive c)
c fos Percentage positivity
Mean±S.D
Squamous cell carcinoma 50(35) 44.5±36.9%
Premalignant 50(19) 11.4±18.8%
Mild dysplasia 36(12) 10.85±14.23%
Moderate dysplasia 14(7) 19.64 ± 26.05%.
Controls 30(5) 1.23±2.6%
Table 2.  c-fos expression in squamous cell carcinoma, premalignant lesions and controls.
p<0.001,Kruskal Wallis test
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creasing c fos expression with normal oral mucosa having 
the lowest, premalignant lesions having intermediate and 
SCC having the highest expression.  We found that c fos is 
over expressed in 70% of squamous cell carcinoma of oral 
cavity, 38% of premalignant lesions and 16% in normal 
oral mucosa. Similar study was done by Cheung et al (12) 
to evaluate the role of c fos in cervical malignant and pre-
malignant lesions. They found that c fos is over expressed 
in cervical carcinoma (59%) compared to premalignant 
lesions (10%) and had no expression in normal cervical 
tissue. Similarly Lee et al (14) also found c fos expression 
in 75% of adenocarcinoma, 22% of chronic pancreatitis 
and 40% of normal pancreas. Thus, these studies along 
with ours prove that c fos expression increases significantly 
as we move from normal to premalignant to squamous 
cell carcinoma, the premalignant cases being intermediate. 
This variation in positivity is statistically significant. The 
result suggests a role of c fos in malignant transformation 
in oral cavity. It was further seen that moderate dysplasia 
had more c fos expression compared to mild dysplasia. 
Thus c fos plays an important role in malignant trans-
formation and its progression and thus is an early event 
starting at the level of  leucoplakia or oral submucous 
fibrosis and progresses to develop dysplasia and ultimately 
transforming to malignancy. This is different than that 
found by Saez et al (3) who found it to be a late event in 
mouse skin carcinogenesis. This being an animal model 
may not truly reflect the human carcinogenesis.
Thus to conclude, various extra cellular and environmen-
tal stimuli such as tobacco and other tumour promoters 
(19), UV light (19), X-ray (20) and alkylating agents (21) 
induce expression of the immediate early genes such as c 
fos and c jun. Together they form a transcription factor 
AP-1(11) which plays a role in mediating tumorigenic 
transformation and growth, which in oral cancers takes 
almost a decade. 
References
1. Parkin DM, Läärä E, Muir CS. Estimates of the worldwide frequency 
of sixteen major cancers in 1980. Int J Cancer. 1988 Feb 15;41(2):184-
97. 
2. Nieto A, Ramos MR. Rising trends in oral cancer mortality in Spain, 
1975-94. J Oral Pathol Med. 2002 Mar;31(3):147-52. 
3. Saez E, Rutberg SE, Mueller E, Oppenheim H, Smoluk J, Yuspa SH, 
et al. C-fos is required for malignant progression of skin tumors. Cell. 
1995 Sep 8;82(5):721-32. 
4. Küffer R, Lombardi T. Premalignant lesions of the oral mucosa. A 
discussion about the place of oral intraepithelial neoplasia (OIN). Oral 
Oncol. 2002 Feb;38(2):125-30. 
5. No authors listed. Control of oral cancer in developing countries. A 
WHO meeting. Bull World Health Organ. 1984;62(6):817-30. 
6. Chimenos-Küstner E, Font-Costa I, López-López J. Oral cancer risk 
and molecular markers. Med Oral Patol Oral Cir Bucal. 2004 Nov-
Dec;9(5):381-4; 377-80. 
7. Jayant K. Statistical appraisal of  the association of smoking and 
chewing habits to oral and pharyngeal cancers. Indian J Cancer. 1977 
Dec;14(4):293-9. 
8. Muir CS, Kirk R. Betel, tobacco, and cancer of the mouth. Br J 
Cancer. 1960 Dec;14:597-608. 
9. Murti PR, Bhonsle RB, Gupta PC, Daftary DK, Pindborg JJ, Mehta 
FS. Etiology of oral submucous fibrosis with special reference to the role 
of areca nut chewing. J Oral Pathol Med. 1995 Apr;24(4):145-52. 
10. Volm M, Efferth T, Mattern J. Oncoprotein (c-myc, c-erbB1, c-erbB2, 
c-fos) and suppressor gene product (p53) expression in squamous cell 
carcinomas of the lung. Clinical and biological correlations. Anticancer 
Res. 1992 Jan-Feb;12(1):11-20. 
11. Lee W, Haslinger A, Karin M, Tjian R. Activation of transcription 
by two factors that bind promoter and enhancer sequences of the human 
metallothionein gene and SV40. Nature. 1987 Jan 22-28;325(6102):368-
72. 
12. Cheung TH, Leung JO, Chung TK, Lam SK, To KF, Wong YF. 
C-fos overexpression is associated with the pathoneogenesis of invasive 
cervical cancer. Gynecol Obstet Invest. 1997;43(3):200-3. 
13. Wodrich W, Volm M. Overexpression of oncoproteins in non-small cell 
lung carcinomas of smokers. Carcinogenesis. 1993 Jun;14(6):1121-4. 
14. Lee CS, Charalambous D. Immunohistochemical localisation of 
the c-fos oncoprotein in pancreatic cancers. Zentralbl Pathol. 1994 
Aug;140(3):271-5. 
15. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, et 
al. The proto-oncogene c-fos is over-expressed in the majority of human 
osteosarcomas. Oncogene. 1990 Jul;5(7):989-1000. 
16. Arbuthnot P, Kew M, Fitschen W. C-fos and c-myc oncoprotein 
expression in human hepatocellular carcinomas. Anticancer Res. 1991 
Mar-Apr;11(2):921-4. 
17. Magrisso IJ, Richmond RE, Carter JH, Pross CB, Gilfillen RA, Car-
ter HW. Immunohistochemical detection of RAS, JUN, FOS, and p53 
oncoprotein expression in human colorectal adenomas and carcinomas. 
Lab Invest. 1993 Dec;69(6):674-81. 
18. Turatti E, Da Costa Neves A, De Magalhães MH, De Sousa SO. 
Assessment of c-Jun, c-Fos and cyclin D1 in premalignant and malignant 
oral lesions. J Oral Sci. 2005 Jun;47(2):71-6. 
19. Büscher M, Rahmsdorf HJ, Litfin M, Karin M, Herrlich P. Activation 
of the c-fos gene by UV and phorbol ester: different signal transduc-
tion pathways converge to the same enhancer element. Oncogene. 1988 
Sep;3(3):301-11. 
20. Woloschak GE, Chang-Liu CM. Differential modulation of specific 
gene expression following high- and low-LET radiations. Radiat Res. 
1990 Nov;124(2):183-7. 
21. Hollander MC, Fornace AJ Jr. Induction of fos RNA by DNA-
damaging agents. Cancer Res. 1989 Apr 1;49(7):1687-92. 
Acknowledgements:
We would specially like to thank Ms Navneet Saini and Mr. Suresh 
Hedau for their immense help during the study.
